Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1102 Nifty 500 stocks· EOD 2026-06-18

Lincoln Pharmaceuticals Limited

LINCOLN · NSE · Healthcare

₹608.75
-21.00 (-3.33%)
Buy zoneBuy
The bottom line

StocksWizard rates Lincoln Pharmaceuticals Limited a Buy, scoring 67/100 on our blended model. At ₹608.75 it trades below our blended DCF and relative-multiples fair value of ₹1,217.5, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 100/100 (grade A), in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 10 of 13 investability checks, with durability 62, valuation 100 and momentum 49 on our 0–100 scales.

These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Our verdict
Buy67/100
Quality62
Valuation100
Momentum49
Financial trend45
Intrinsic value
Our fair value
₹1,217.5
Undervalued by 100%
Price ₹608.75Range ₹404.24₹1,314.9

With a 20% margin of safety, our buy-below price is ₹974. Low-confidence estimate — limited data.

A
Financial health 100/100
Altman Z 7.5 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Investability checklist

Passed 10 of 13 checks77/100
  • ROE above 15%12.3%
  • Low debt (D/E < 0.5)0.01x
  • Positive free cash flow
  • Revenue growth > 10%11%
  • Earnings growing1%
  • Net margin ≥ 10%13.1%
  • Current ratio > 1.55.25
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 7.5
  • Piotroski ≥ 74/9

1-year price

EOD · 2026-06-18
1W
-3.3%
1M
-13.7%
3M
+4.2%
6M
+28.3%
1Y

Our scores

Durability62
Valuation100
Momentum49

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Quarterly results

4Q2019₹99 Cr revenue
Net profit ₹0 Cr0% margin
1Q2020₹78 Cr revenue
Net profit ₹0 Cr0% margin
2Q2020₹104 Cr revenue
Net profit ₹0 Cr0% margin
3Q2020₹126 Cr revenue
Net profit ₹0 Cr0% margin
Revenue Net profitLatest revenue QoQ +21%

Annual financials

2017₹364 Cr revenue
Net profit ₹0 Cr0% margin
2018₹366 Cr revenue
Net profit ₹0 Cr0% margin
2019₹372 Cr revenue
Net profit ₹0 Cr0% margin
2020₹386 Cr revenue
Net profit ₹0 Cr0% margin
Revenue Net profitLatest revenue YoY +4%

Shareholding

Promoter56.1%
Institutions1.1%
Public & other42.8%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹1,219 Cr
P/E ratio
13.9
P/B ratio
1.61
EPS (TTM)
₹43.86
ROE
12.3%
Debt / Equity
0.01x
Profit margin
13.1%
Free cash flow
₹3 Cr
52-week high
₹758.15
-19.71% from high
52-week low
₹444.2
Dividend yield
Beta
0.35

SWOT snapshot

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 7.5.

Opportunities

  • Trading in our value buy zone versus sector peers.
  • Trades ~100% below our estimated fair value.

About Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada

More in Healthcare

All stocks

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.